Ohio State Navbar

Directory

Jeffrey Jones, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 688-7942

Email: jones.2685@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Hematology;Medical Oncology

Academic Advising

2010 - present Emily Dotson, The Ohio State University. Graduated 2011.
2011 - present Galena Salem, Ohio State University College of Medicine. Graduated 2013.
2013 - present Kerry Rogers, Ohio State University College of Medicine.
2008 , The Ohio State University.
2006 - 2010 Cory Darrow, The Ohio State University. Graduated 2010.
2009 - 2010 Samantha Jaglowski, The Ohio State University. Graduated 2010.
2010 , The Ohio State University.
 

Licenses

2003 - present Board Certification: American Board of Internal Medicine
2004 - present Fundamental Critical Care Support: MD Anderson Medical Center
2006 - present Medical License: State Medical Board of Ohio
2006 - present Board Certification: American Board of Internal Medicine
2006 - present Certificate: American Heart Association
2006 - present Board Certification: American Board of Internal Medicine
2006 - present Certificate: American Heart Association
2000 - 2003 Quebec Resident Training Card: College des Medecins du Quebec
2004 Certificate: National Cancer Institute
2003 - 2006 Medical License: Texas Medical Board
 

Conferences

Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).

Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).

Del(17p13.1) in chronic lympliucytic leukemia confers poor prognosis even at low percentage involvement and increases proportionately with. increase in clonal involvement

Low incidence of opportunistic infections in CLL patients treated with single agent flavopiridol

Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation.

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma

Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)

CAL-101, a Selective Inhibitor of the p110 delta Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Second primary malignancies after chronic lymphocytic leukemia

Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care

Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL

Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)

Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease

In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody

Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Early Evidence of Anti-Lymplioma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701-a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

MUTATION STATUS AND PREFERRED UTILIZATION OF IGVH GENE IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATIONS WITH COMMON BIOLOGIC ABNORMALITIES

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-delta Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia.

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma

FINAL RESULTS OF A PHASE I-II CLINICAL TRIAL OF OXALIPLATIN, FLUDARABINE, CYTARABINE, AND RITUXIMAB (OFAR) COMBINATION THERAPY IN PATIENTS WITH AGGRESSIVE, RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND RICHTER SYNDROME (RS)

Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

A phase Ib/II study evaluating activity and tolerability of the BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity

Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia

COMPLEX KARYOTYPE (CK) IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA (MCL) IN FIRST REMISSION

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies

Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL

Beyond scaffolding: CD37 tetraspanin as therapeutic target in leukemia-mechanism based novel combination opportunities with emerging kinase inhibitors

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

 

Degrees

1992 B.A., University of Maryland

1992 B.A., University of Maryland

2000 M.D., University of Michigan

2006 M.Public Hlth., The University of Texas Health Science Center at Houston

 

Editorial Activities

2008 - present Leukemia and Lymphoma
2009 - present Cancer
2009 - present Drugs
2009 - present Stem Cells & Development
2010 - present Expert Review of Hematology
2010 - present Diabetes Research and Clinical Practice
2013 - present Clinical Lymphoma, Myeloma, and Leukemia
2013 - present American Journal of Clinical and Experimental Immunology
 

Honors

1992 Phi Beta Kappa.
1992 Commencement Speaker.
1992 - 1998 Maryland Distinguished Scholar.
1996 - 2000 Ralph L. Morse Medical Scholarship.
2000 Alpha Omega Alpha.
2000 - 2001 Eli G. Rochelson Award. University of Michigan Medical School.
2005 - 2006 ASCO Merit Award. ASCO.
2007 - 2008 ASCO Young Investigator Award. ASCO.
2008 - 2009 Outstanding Faculty Educator. OSU Internal Medicine Student Programs.
 

Journal Articles

"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes." BLOOD. Vol. 122, no. 15. (October 2013.): -.

"Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing." BLOOD. Vol. 122, no. 19. (November 2013.): -.

 

Reference Works

July 2005 Jones JA, Qazilbash MH, Shih YT, Cantor SB, Cooksley CD, Elting LS."Economic Implications of Outcomes Complicating Hematopoetic Stem Cell Transplant for Multiple Myeloma and Lymphoma" .
July 2005 Jones JA, Lu C, Cooksley CD, Shih YCT, Elting LS."The Incidence Outcomes, and Economic Burden of Hospitalizations for Common Medical Complications in Patients with Lung Cancer: A Population-Based Study" .
May 2005 Jones JA, Qazilbash MH, Shih YT, Cantor SB, Cooksley CD, Elting LS."Economic Implications of Outcomes Complicating Hematopoeitic Stem Cell Transplant (HSCT) for Multiple Myeloma and Lymphoma" .
November 2007 Lin T, Fischer B, Blum K, Andritsos L, Jones JA, Moran M, Broering S, Heerema N, Lozanski G, Schaaf L, Mohoney L, Johnson A, Smith L, Wagner A, Raymond C, Phelps M, Dalton J, Grever MR, Byrd JC."Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses" . : 3104
November 2007 Andritsos A, Fischer B, Lin T, Blum K, Jones JA, Moran M, Byrd JC, Grever MR."Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol" . : 3128
November 2007 Andritsos L, Jones JA, Lozanski G, Lin T, Blum K, Grever MR, Jarjoura D, Byrd JC, Heerema N."del(17p13.1) in Chronic Lymphcytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement" . : 2073
November 2007 Heerema N, Byrd JC, Andritsos A, Lozanski G, Blum K, Fischer B, Jones JA, Moran M, Groering S, Schaaf L, Mahoney L, Johnson A, Smith L, Wagner A, Raymond C, Phelps M, Dalton J, Grever MR, Lin T."Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients" . : 3107
November 2008 May S, Kashishian A, Lin T, Jones JA, Flynn J, Ulrich R, Chen H, Yu A, Puri K, Lannutti B, Giese N, Byrd JC, Johnson AJ."CAL-101, a Selective Inhibitor of the p110 Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of this Disease" . : 3169
November 2008 Jones JA, Flynn J, Byrd JC."Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)" . : 873
November 2008 Jones JA, Byrd JC, Flynn J, Hofmeister C."Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care" . : 2409
November 2008 Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones JA, Blum W, Elder P, Lozanski Gerard, Byrd JC, Devine S."Natural Killer Cell Immune Recontitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation" . : 3300
June 2008 Flynn J, Andritsos L, Lin T, Byrd JC, Jones JA."Second Primary Malignancies and Chronic Lymphocytic Leukemia" .
November 2008 Lin T, Heerema N, Lozanski G, Fischer B, Blum K, Andritsos L, Jones JA, Flynn J, Moran M, Mitchell S, Johnson AJ, Phelps M, Grever M, Byrd JC."Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities" . : 46
November 2008 Blum K, Liu Z, Lucas D, Baiocchi R, Lin T, Benson D, Devine S, Jones JA, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan K, Grever M, Byrd JC."A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation." . : 3169
November 2008 Blum K, Baiocchi R, Alinari L, Lin T, Porcu P, Jones JA, Flynn J, Hicks W, Lucas M, Wei L, Johnston J, Byrd JC."A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma" . : 3053
November 2008 Andritos L, Hamadani M, Heerema N, Benson D, Hofmeister C, Blum W, Flynn J, Jones JA, Elder P, Lin T, Lozanski G, Byrd JC, Devine S."Attainment of Minimal Residual Disease Negative State is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia" . : 2170
June 2008 Lin T, Andritsos L, Jones JA, Fischer B, Heerema N, Blum K, Flynn J, Moran M, Mitchell S, Lozanski G, Schaaf L, Johnson A, Smith L, Wagner A, Raymond C, Phelps M, Dalton J, Grever MR, Byrd JC."The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol is Highly Active in Relapsed, Genetically High Risk Chronic Lymphocytic Leukemia (CLL)" .
January 2009 Tsimberidou A, Wierda W, Plunkett W, O'Brien S, Kipps T, Jones JA, Smith S, Jalayer A, Kantarjian H, Keating M."Oxaliplatin, Fludarabine, Cytarabine, and Rituximab combination therapy induces high response rates in aggressive chronic lymphocytic leukemia (CLL) and Richter's Syndrome (RS)" .
January 2009 Jones JA, Flynn J, Moran M, Lin T, Byrd JC."Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)" . : abstr e20500
November 2009 Flynn J, Johnson A, Andritsos L, Blum K, Jones JA, Wiley E, Hu W, Hessler J, Smith L, Lucas D, Small K, Statkevich P, Grever M, Bannerji R, Byrd JC."The cyclin dependent kinase inhibitor SCH 72795 demonstrates promising pre-clinical and early clinical activity in chronic lymphocytic leukemia" .
November 2009 Awan F, Lapalombella R, Trotta R, Buchar J, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn J, Jarjoura D, Baiocchi R, Desjarlais J, Tridandapani S, Caligiuri M, Muthusamy N, Byrd JC."CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monclonal Antibody" .
November 2009 Jaglowski S, Byrd J, Jones JA."In-hospital mortality and trends associated with splenectomy in patients with immune-medicated thrombocytopenia (ITP)" .
November 2009 Woyach J, Byrd JC, Zhao J, McFaddin A, Ruppert A, Lin TS, Andritsos L, Blum K, Flynn J, Jones JA, Heerema N."Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukemia associated with aggressive disease" .
November 2010 Baiocchi RA, Flynn JM, Jones JA, Blum KA, Hofmeister CC, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients" . : Abstract #3966
November 2010 Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Kantarjian HM, Keating MJ."Results of a phase I-II clinical trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)" . : Abstract #923
November 2010 Christian B, Alinari L, Earl CT, Wilding E, Quinion C, Lustberg M, Benson DM, Jones JA, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA."A phase I study of Milatuzumab a humanized anti-CD74 antibody and Veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-Cell Non-Hodgkin's Lymphoma" . : Abstract #2788
November 2010 Jones JA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Deam D, Flynn JM, Johnson AJ, Phelps MA, Porcu P, Byrd JC, Grever MR."Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's lymphoma" . : Abstract #2834
November 2010 Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC."Dinaciclib (SCH727965) is a novel cyclin dependent kinase inhibitor that promotes selective apoptosis in CLL cells and abrogates the protective effects of microenvironment cytokines" . : Abstract #971
November 2010 Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps T, Hsu FJ, Burger JA."Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of Plerixafor in combination with Rituximab in patients with relapsed chronic lymphocytic leukemia" . : Abstract #2450
November 2010 Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta S, Herman S, Andritsos L, Jones JA, Flynn JM, Lucas DM, Grever MR, Byrd JC."Autophagy is a relevant cellular process in CLL and contributes to drug resistance of Flavopiridol" . : Abstract #691
November 2010 Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA."Response, progression-free survival and overall survival of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with Flavopiridol: Impact of poor risk cytogenetic abnormalities" . : Abstract #2456
November 2010 Stephens DM, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Ji J, Phelps M, Grever M, Byrd JC."Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is feasible and not associated with adverse outcome when compared to younger patients" . : Abstract #1378
November 2010 Kipps TJ, Wierda WG, Jones JA, Swinnen LJ, Yang J, Cui Y, Busman T, Krivshik A, Enschede S, Humerickhouse R."Navitoclax (AABT-263) plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A phase I study in patients with relapsed refractory chronic lymphocytic leukemia (CLL)" . : abstract 2455
November 2010 Hofmeister CC, Bowers MA, Lee S, Phelps MA, Benson DM, Kraut EH, Hicks WJ, Deam D, Johnson AJ, Farag F, Jones JA, Byrd JC."Phase I trial of Flavopiridol in relapsed myeloma: Brief response in t(4;14) with significant neutropenia" . : Abstract #1933
November 2010 Grant B, Leonard JP, Johnson JL, Kostakoglu L, His E, Byrd JC, Jones JA, Jung SH, Cheson BD."Combination biologic therapy as initial treatment for follicular lymphoma: Initial results from CALGB 50701 - A phase II trial of extended induction Epratuzumab (anti-CD22) adn Rituximab (anti-CD20)" . : Abstract #427
November 2010 Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."Update on the phase I study of the cyclin dependent kinase inhibitor Dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Confirmation of clinical activity and feasibility of long-term administration" . : Abstract #1396
November 2010 Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC."Risk factors for tumor lysis syndrome (TLS) in patients with Chronic Lymphocytic Leukemia (CLL) treated with the cyclin dependent kinase inhibitor, Flavopiridol" . : Abstract #1386
January 2010 Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett S, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ."Evaluation of oxaliplatin, fludarabine, cytarabine, adn rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's Syndrome (RS)" . : suppl; abstr 6521
November 2010 Jaglowski SM, Flynn JM, Jones JA, Lin TS, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC, Andritsos L."Flavopiridol is an effective therapy to bridge patients with chronic lymphocytic leukemia (CLL) to reduce-intensity conditioning allogeneic stem cell transplant" . : Abstract #2383
November 2010 Herman S, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson AJ."Lenalidomide-dependent activation of the phosphatidylinositol 3-kinase- pathway is antagonized by CAL-101 in chronic lymphocytic leukemia" . : Abstract #1821
November 2010 Blum KA, Jones JA, Andritsos L, Flynn JM, Deam D, Heerema N, Phelps M, Johnson AJ, Grever MR, Byrd JC."A phase I trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia (CLL)" . : Abstract #2472
January 2011 Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Gessler J, Wiley E, Heerema NA, Poon J, Small KA, Jou Y, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC."A phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL" . : Abstract #6623
November 2011 Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR, Byrd JC."Activity of combined Flavopiridol and Lenalidomide in patients with cytogenetically high risk chronic lymphocytic leukemia: Updated results of a phase I trial" . : abstr 3910
November 2011 Cohen JB, Hall N, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Penza S, Benson DM, Andritsos LA, Flynn JM, Devine SM, Blum KA."The prognostic value of FDG PET/CT prior to autologous stem cell transplant in mantel cell lymphoma" . : abstr 3113
November 2011 Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S, Humerickhouse R."Navitoclax (ABT-263) plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A phase I study in patients with relapsed/refractory chronic lymphcytic leukemia (CLL)" .
November 2011 Jones JA, Stark A, Zhao W, Lin TS, Rai KR, Marcucci G, Peterson B, Larson RA, Heerema NA, Byrd JC."Alemtuzumab consolidation does not improve outcome for CLL patients with high risk genomic features on successive CALGB trials" . : abstr 1791
November 2011 Finn IW, Harwin WN, Marcias-Perez IM, Tucker PS, Waterhouse DM, Papish SW, Jones JA, Hainesworth JD, Byrd JC."A phase II trial of Ofatumumab for older patients and patients who refuse Fludarabine-based regimens with previously untreated chronic lymphcytic leukemia or small lymphocytic lymphoma" .
November 2011 Lapalombella R, Ramanunni A, Yeh YY, Wang L, Jha S, Staubil J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC."Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals" . : abstr 622
November 2011 Christian B, Alinari L, Jones JA, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, Blum KA."Results of a phase I study of Milatuzumab, a humanized anti-CD74 antibody and Veltuzumab, a anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma" . : abstr 3707
June 2012 Jaglowski SM, Jones JA, Flynn JM, Andritsos LA Maddocks K, Blum KA, Grever MR, Geyer SM, Woyach J, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC."A phase Ib/II study evaluation activity and tolerability of BTK inhibitor PCI-32765 and ofactumumab in patients with chronic lymphocytic leukemia/small lymphcytic lymphoma (CLL/SLL) and related diseases" . : abstr 6508

Presentations

Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions among Patients with Lymphoid Malignancies

Prognostic Factors and Treatment for Chronic Lymphocytic Leukemia: Clinical Strategies in 2008

New Agents on the Horizon for CLL

What are the new drugs on the horizon that my patients will ask me about

Abrogating the Cell Cycle in Chronic Lymphocytic Leukemia

New Agents on the Horizon for Chronic Lymphocyic Leukemia

Role of Old and New Monoclonal Antibodies, Alone and in Combinations

Treatment Options for CLL: Emerging Data

Anthracycline-based chemoimmunotherapy + ibrutinb for Richter's transformation of CLL

17p and 11q deletions in CLL

The sum of experience from CALGB: Focus on elderly patients

Phase 1 Study of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (SCH727965) in Relapsed/Refractory CLL

Inhibition of BTK: A Promising New Approach

CLL Today: Context for GS-1101 Development

CLL Therapy, excluding Transplantation: New Targeted Therapies

Novel Agents in Development for Treatment of Patients with CLL

Should rituximab-bendamustine be utilized as frontline therapy for symptomatic CLL or held in reserve for salvage therapy?

Recent Advances in Chronic Lymphocytic Leukemia

Mechanisms of toxicity of PI3K-delta inhibitors

Chronic Lymphocytic Leukemia: Putting on a New Face

Current Standard of Care and Treatment Paradigms: Relapsed/Refractory CLL

Combination Kinase Inhibitor Therapy for Relapsed/Refractory CLL

Targeting Novel Signaling Pathways in B-cell Malignancies

A Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Update on CLL

Choosing Upfront Therapy for Patients With Chronic Lymphocytic Leukemia

CLL 2015: How do we convert chronic disease to a curable disease?

Molecular Targeted Therapy for CLL: (Re-) Making CLL History

Ibrutinib for Relapsed Hairy Cell Leukemia: Early Results of an Ongoing Trial

Chronic Lymphocytic Leukemia

Factors Driving Resistance to Ibrutinib

BTKI Treatment Failure: Patterns and Mechanisms of Resistance

New Agents in Chronic Lymphocytic Leukemia

 

Professional Activities

present Invited Speaker. Central Ohio Chapter, Leukemia and Lymphoma Society.
present Invited Speaker. Central Ohio Chapter, Leukemia and Lymphoma Society.
present Academic National Advisory Board. Bristol Myers Squibb.
present Gilead CLL Academic Advisory Board. Gilead Pharmaceuticals.
present Academic National Advisory Board for Ofatumumab in CLL. GlaxoSmithKline.
present New Agents of Interest in Lymphoma Advisory Board. Celgene.
present Ibrutinib Academic Advisory Board (Mantle Cell lLymphoma indications). Pharmacyclics, Inc..
present NCI CLL Working Group.
2011 - 2001 Velcade Advisory Board. Millennium Pharmaceuticals.
 

Unpublished Works

The CD37-targeting antibody-drug conjugate IMGN529 is efficacious in a novel human CD37-positive mouse leukemia model